GNPX Genprex

NetworkNewsAudio Announces Audio Press Release (APR) on Genprex Inc.'s Transformative Work in Gene Therapy

New York, New York--(Newsfile Corp. - March 15, 2019) - NetworkNewsAudio announces the Audio Press Release (APR) titled "Making Profits, Saving Lives with Gene Therapy," featuring Genprex Inc. (NASD: GNPX).

To hear the NetworkNewsAudio version, visit:

To read the full editorial, visit:

This evidence of the faith of the markets has helped boost stock values for a range of gene therapy companies, with . But these companies don't need to be the targets of mergers to benefit from this. A rising tide lifts all boats, and a shift in perspective that sees gene therapy as a mature and profitable endeavor increases confidence in companies such as Genprex, which are still working away in their own corners.

Gene therapy saves lives by altering the genetic makeup of a cell. Diseases can be caused by faulty copies of genes that don't create the proteins they should within a cell. The insertion of better genes can restore function to the cell, building a healthier body from the most basic building blocks up. That's why the work of companies such as Genprex can be so transformative.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex's initial product candidate, Oncoprex(TM) immunogene therapy for non-small cell lung cancer (NSCLC). Genprex's platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. For more information, visit the company's website at .

About NetworkNewsAudio

, a Solution, allows you to sit back and listen to market updates, CEO interviews and a Company . These audio clips provide snapshots of position, opportunity and momentum. can assist your company by cutting through the overload of information in today's market, NNA brings its clients unparalleled visibility, recognition and brand awareness. is where news, content and information converge. is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.

For more information, visit:

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: .

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Corporate Communications:

NetworkWire (NW)
New York, New York

212.418.1217 Office

To view the source version of this press release, please visit

EN
15/03/2019

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genprex

 PRESS RELEASE

Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immun...

Genprex Inc. (NASDAQ: GNPX) Receives Orphan Drug Designation for Immunogene Therapy for Treatment of SCLC NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- via — Genprex Inc. (NASDAQ: GNPX) today announces its placement in an editorial published by ("NNW"), one of 50+ trusted brands within the (“IBN”), a multifaceted financial news and publishing company for private and public entities. To view the full publication, “Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation,” please visit: More than 30 million people in the United States suffer with a r...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Daily Ratings Report: April 24, 2023

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

 PRESS RELEASE

Genprex Announces the Opening for Enrollment of its Phase 1/2 Acclaim-...

AUSTIN, Texas--(BUSINESS WIRE)-- (“Genprex” or the “Company”) (NASDAQ: ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the opening for patient enrollment of its Acclaim-2 clinical trial. Acclaim-2 is an open-label, multi-center Phase 1/2 clinical trial evaluating the Company’s lead drug candidate, REQORSA™ Immunogene Therapy, in combination with Keytruda® (pembrolizumab) in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with Keytruda. In 2021, Gen...

 PRESS RELEASE

Genprex to Participate in Upcoming Investor Conference in March

AUSTIN, Texas--(BUSINESS WIRE)-- (“Genprex” or the “Company”) (NASDAQ: ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its President and Chief Executive Officer, Rodney Varner, will provide an overview of the Company’s gene therapies for cancer and diabetes to investors at the 2022 BIO Europe Spring Investor Conference. Conference Details: Event: BIO Europe Spring Investor Conference Conference Dates: March 28-31, 2022 Presentation Time: Available on-demand throughout duration of the conferenc...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch